Following the first clinical report on CD44 expression in T-ALL, very few clinical-translational approaches were performed to test the value of CD44 as a marker either in tumor expansion or its relevance in the role of T-ALL outcome. This evidence concerns the gene CD44 and acute lymphoblastic leukemia.